Supernus Pharmaceuticals Pre-Paid Expenses 2011-2024 | SUPN
Supernus Pharmaceuticals pre-paid expenses from 2011 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
Supernus Pharmaceuticals Annual Pre-Paid Expenses
(Millions of US $) |
| 2023 |
$17 |
| 2022 |
$16 |
| 2021 |
$27 |
| 2020 |
$19 |
| 2019 |
$12 |
| 2018 |
$9 |
| 2017 |
$7 |
| 2016 |
$3 |
| 2015 |
$5 |
| 2014 |
$4 |
| 2013 |
$3 |
| 2012 |
$1 |
| 2011 |
$0 |
| 2010 |
$ |
Supernus Pharmaceuticals Quarterly Pre-Paid Expenses
(Millions of US $) |
| 2024-09-30 |
$27 |
| 2024-06-30 |
$23 |
| 2024-03-31 |
$24 |
| 2023-12-31 |
$17 |
| 2023-09-30 |
$24 |
| 2023-06-30 |
$45 |
| 2023-03-31 |
$16 |
| 2022-12-31 |
$16 |
| 2022-09-30 |
$25 |
| 2022-06-30 |
$21 |
| 2022-03-31 |
$22 |
| 2021-12-31 |
$27 |
| 2021-09-30 |
$31 |
| 2021-06-30 |
$34 |
| 2021-03-31 |
$18 |
| 2020-12-31 |
$19 |
| 2020-09-30 |
$24 |
| 2020-06-30 |
$20 |
| 2020-03-31 |
$13 |
| 2019-12-31 |
$12 |
| 2019-09-30 |
$18 |
| 2019-06-30 |
$22 |
| 2019-03-31 |
$21 |
| 2018-12-31 |
$9 |
| 2018-09-30 |
$9 |
| 2018-06-30 |
$15 |
| 2018-03-31 |
$7 |
| 2017-12-31 |
$7 |
| 2017-09-30 |
$6 |
| 2017-06-30 |
$5 |
| 2017-03-31 |
$5 |
| 2016-12-31 |
$3 |
| 2016-09-30 |
$4 |
| 2016-06-30 |
$3 |
| 2016-03-31 |
$5 |
| 2015-12-31 |
$5 |
| 2015-09-30 |
$6 |
| 2015-06-30 |
$4 |
| 2015-03-31 |
$4 |
| 2014-12-31 |
$4 |
| 2014-09-30 |
$4 |
| 2014-06-30 |
$3 |
| 2014-03-31 |
$3 |
| 2013-12-31 |
$3 |
| 2013-09-30 |
$2 |
| 2013-06-30 |
$2 |
| 2013-03-31 |
$1 |
| 2012-12-31 |
$1 |
| 2012-09-30 |
$1 |
| 2012-06-30 |
$1 |
| 2012-03-31 |
$1 |
| 2011-12-31 |
$0 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
